Biopharma’s bolt-on bonanza is set to continue
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
JP Morgan 2023 – day one sees buyers make the most of straitened times
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Takeout premiums hold up, but that’s not the whole story
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
